H1B Report
Side-by-side comparison

INFOSYS LIMITED vs Takeda Pharmaceuticals America Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
INFOSYS LIMITED
TXRank #1FEIN 58-1760235
Entity B
Takeda Pharmaceuticals America Inc.
MARank #FEIN 36-4394197

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricINFOSYS LIMITEDTakeda Pharmaceuticals America Inc.
Total filings200,32924
Certified %99.55%87.50%
Denied %0.21%0.00%
Withdrawn %0.20%0.00%
Cert-withdrawn %0.05%12.50%
Rank#1
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateTXMA

Outcomes — INFOSYS LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.5%, Cert-withdrawn 0.0%, Withdrawn 0.2%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%

Outcomes — Takeda Pharmaceuticals America Inc.

DOL case-status mix.

Outcome breakdown: Certified 87.5%, Cert-withdrawn 12.5%
Outcome breakdown
OutcomeShare
Certified87.5%
Cert-withdrawn12.5%
Certified87.5%
Cert-withdrawn12.5%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

INFOSYS LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,138
FY20111,681
FY201214,633
FY201331,994
FY201423,467
FY201532,976
FY201624,049
FY201720,254
FY201811,519
FY201921,102
FY202016
FY202129
FY202222
FY20232,269
FY20245,943
FY20255,790
FY20262,447
Takeda Pharmaceuticals America Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20105
FY20116
FY20120
FY20130
FY20140
FY20150
FY20160
FY20170
FY20180
FY20190
FY20202
FY20211
FY20220
FY20231
FY20245
FY20253
FY20261

Top 5 occupations — INFOSYS LIMITED

Top 5 occupations — Takeda Pharmaceuticals America Inc.

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.